169 related articles for article (PubMed ID: 35247595)
21. Benralizumab in Patients with Severe Eosinophilic Asthma: A Multicentre Real-Life Experience.
Scioscia G; Tondo P; Nolasco S; Pelaia C; Carpagnano GE; Caiaffa MF; Valenti G; Maglio A; Papia F; Triggiani M; Crimi N; Pelaia G; Vatrella A; Foschino Barbaro MP; Crimi C
J Clin Med; 2023 Jun; 12(13):. PubMed ID: 37445397
[TBL] [Abstract][Full Text] [Related]
22. Benralizumab efficacy for patients with fixed airflow obstruction and severe, uncontrolled eosinophilic asthma.
Chipps BE; Hirsch I; Trudo F; Alacqua M; Zangrilli JG
Ann Allergy Asthma Immunol; 2020 Jan; 124(1):79-86. PubMed ID: 31626906
[TBL] [Abstract][Full Text] [Related]
23. Impact of mepolizumab on exacerbations in severe asthma: Results from a U.S. insurance claims data base.
Ortega H; Hahn B; Bogart M; Bell CF; Bancroft T; Chastek B; Llanos JP
Allergy Asthma Proc; 2020 Sep; 41(5):341-347. PubMed ID: 32867888
[No Abstract] [Full Text] [Related]
24. Real-life cost-effectiveness of benralizumab in patients with severe asthma.
Padilla-Galo A; García-Ruiz AJ; Levy Abitbol RC; Olveira C; Rivas-Ruiz F; García-Agua Soler N; Pérez Morales M; Valencia Azcona B; Tortajada-Goitia B; Moya-Carmona I; Levy-Naon A
Respir Res; 2021 May; 22(1):163. PubMed ID: 34044819
[TBL] [Abstract][Full Text] [Related]
25. Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study.
Menzies-Gow A; Gurnell M; Heaney LG; Corren J; Bel EH; Maspero J; Harrison T; Jackson DJ; Price D; Lugogo N; Kreindler J; Burden A; de Giorgio-Miller A; Padilla K; Martin UJ; Garcia Gil E
Lancet Respir Med; 2022 Jan; 10(1):47-58. PubMed ID: 34619104
[TBL] [Abstract][Full Text] [Related]
26. Reduction in asthma exacerbation rate after mepolizumab treatment initiation in patients with severe asthma: A real-world database study in Japan.
Nagase H; Tamaoki J; Suzuki T; Nezu Y; Akiyama S; Cole AL; Yang S; Mu G; Katsumata M; Komatsubara M; Alfonso-Cristancho R
Pulm Pharmacol Ther; 2022 Aug; 75():102130. PubMed ID: 35714883
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of benralizumab versus mepolizumab and dupilumab in patients with severe uncontrolled eosinophilic asthma in Spain.
Mareque M; Climente M; Martinez-Moragon E; Padilla A; Oyagüez I; Touron C; Torres C; Martinez A
J Asthma; 2023 Jun; 60(6):1210-1220. PubMed ID: 36322679
[TBL] [Abstract][Full Text] [Related]
28. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
Ortega HG; Yancey SW; Mayer B; Gunsoy NB; Keene ON; Bleecker ER; Brightling CE; Pavord ID
Lancet Respir Med; 2016 Jul; 4(7):549-556. PubMed ID: 27177493
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study.
Numata T; Miyagawa H; Nishioka S; Okuda K; Utsumi H; Hashimoto M; Minagawa S; Ishikawa T; Hara H; Araya J; Kuwano K
BMC Pulm Med; 2020 Aug; 20(1):207. PubMed ID: 32746787
[TBL] [Abstract][Full Text] [Related]
30. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.
FitzGerald JM; Bleecker ER; Nair P; Korn S; Ohta K; Lommatzsch M; Ferguson GT; Busse WW; Barker P; Sproule S; Gilmartin G; Werkström V; Aurivillius M; Goldman M;
Lancet; 2016 Oct; 388(10056):2128-2141. PubMed ID: 27609406
[TBL] [Abstract][Full Text] [Related]
31. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Ferguson GT; FitzGerald JM; Bleecker ER; Laviolette M; Bernstein D; LaForce C; Mansfield L; Barker P; Wu Y; Jison M; Goldman M;
Lancet Respir Med; 2017 Jul; 5(7):568-576. PubMed ID: 28545978
[TBL] [Abstract][Full Text] [Related]
32. Identification of distinct phenotypes related to benralizumab responsiveness in patients with severe eosinophilic asthma.
Yamada H; Nakajima M; Matsuyama M; Morishima Y; Arai N; Hida N; Nakaizumi T; Masuko H; Yatagai Y; Saito T; Hizawa N
PLoS One; 2021; 16(3):e0248305. PubMed ID: 33705484
[TBL] [Abstract][Full Text] [Related]
33. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study.
Castro M; Wenzel SE; Bleecker ER; Pizzichini E; Kuna P; Busse WW; Gossage DL; Ward CK; Wu Y; Wang B; Khatry DB; van der Merwe R; Kolbeck R; Molfino NA; Raible DG
Lancet Respir Med; 2014 Nov; 2(11):879-890. PubMed ID: 25306557
[TBL] [Abstract][Full Text] [Related]
34. Mepolizumab add-on therapy in a real world cohort of patients with severe eosinophilic asthma: response rate, effectiveness, and safety.
van Toor JJ; van der Mark SC; Kappen JH; In 't Veen JCCM; Braunstahl GJ
J Asthma; 2021 May; 58(5):651-658. PubMed ID: 31999203
[No Abstract] [Full Text] [Related]
35. Impact of Mepolizumab on Exacerbations in the US Medicare Population.
Sethi S; Bogart M; Corbridge T; Cyhaniuk A; Hahn B
J Allergy Clin Immunol Pract; 2023 Feb; 11(2):546-554.e2. PubMed ID: 36377070
[TBL] [Abstract][Full Text] [Related]
36. Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics.
Liu MC; Chipps B; Munoz X; Devouassoux G; Bergna M; Smith SG; Price RG; Galkin DV; Azmi J; Mouneimne D; Albers FC; Chapman KR
Respir Res; 2021 May; 22(1):144. PubMed ID: 33971856
[TBL] [Abstract][Full Text] [Related]
37. Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma.
Jackson DJ; Humbert M; Hirsch I; Newbold P; Garcia Gil E
Adv Ther; 2020 Feb; 37(2):718-729. PubMed ID: 31836949
[TBL] [Abstract][Full Text] [Related]
38. Real-world effectiveness of mepolizumab in severe asthma and chronic rhinosinusitis in the United States: Impact of comorbidity and sinus surgery.
Silver J; Deb A; Laliberté F; Gao C; Bhattacharyya N
Int Forum Allergy Rhinol; 2024 Jan; 14(1):5-17. PubMed ID: 37365852
[TBL] [Abstract][Full Text] [Related]
39. Real-World Effectiveness of Mepolizumab in Patients with Severe Asthma: An Examination of Exacerbations and Costs.
Llanos JP; Ortega H; Bogart M; Packnett ER; Manjelievskaia J; Bell CF; Hahn B
J Asthma Allergy; 2020; 13():77-87. PubMed ID: 32099413
[TBL] [Abstract][Full Text] [Related]
40. Significant improvement in lung function and asthma control after benralizumab treatment for severe refractory eosinophilic asthma.
Menzella F; Ruggiero P; Galeone C; Scelfo C; Bagnasco D; Facciolongo N
Pulm Pharmacol Ther; 2020 Oct; 64():101966. PubMed ID: 33039666
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
